Short Interest in VolitionRX Limited (NYSEAMERICAN:VNRX) Expands By 101.2%

VolitionRX Limited (NYSEAMERICAN:VNRX) was the target of a large increase in short interest in the month of July. As of July 31st, there was short interest totaling 538,529 shares, an increase of 101.2% from the July 15th total of 267,687 shares. Based on an average daily volume of 308,439 shares, the days-to-cover ratio is presently 1.7 days. Currently, 6.7% of the shares of the stock are sold short.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the company. Maxim Group reaffirmed a “buy” rating and set a $4.00 target price on shares of VolitionRX in a report on Thursday, June 18th. D. Boral Capital reissued a “hold” rating on shares of VolitionRX in a report on Monday, April 20th. Citigroup lowered shares of VolitionRX to a “hold” rating in a research report on Monday, April 20th. Finally, Benchmark reaffirmed a “hold” rating on shares of VolitionRX in a report on Tuesday, June 2nd. Two analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $28.00.

VolitionRX Trading Down 14.8%

Shares of NYSEAMERICAN VNRX traded down $0.09 during midday trading on Friday, hitting $0.54. 952,532 shares of the company’s stock were exchanged, compared to its average volume of 939,791. The business’s fifty day moving average price is $1.13 and its two-hundred day moving average price is $2.74. The company has a market cap of $4.64 million, a price-to-earnings ratio of -0.14 and a beta of 1.16. VolitionRX has a 12-month low of $0.53 and a 12-month high of $15.10.

VolitionRX (NYSEAMERICAN:VNRX) last announced its earnings results on Thursday, August 13th. The medical research company reported ($0.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.28). The company had revenue of $0.40 million for the quarter, compared to analyst estimates of $0.41 million. Equities analysts expect that VolitionRX will post -2.36 earnings per share for the current fiscal year.

Hedge Funds Weigh In On VolitionRX

A number of institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC bought a new stake in shares of VolitionRX during the 4th quarter worth $28,000. Virtu Financial LLC grew its position in VolitionRX by 166.6% in the fourth quarter. Virtu Financial LLC now owns 108,581 shares of the medical research company’s stock worth $28,000 after acquiring an additional 67,848 shares in the last quarter. Squarepoint Ops LLC bought a new position in VolitionRX in the fourth quarter valued at $34,000. Northwestern Mutual Wealth Management Co. bought a new position in VolitionRX in the second quarter valued at $52,000. Finally, Citadel Advisors LLC raised its position in VolitionRX by 70.1% during the third quarter. Citadel Advisors LLC now owns 329,520 shares of the medical research company’s stock valued at $224,000 after purchasing an additional 135,775 shares in the last quarter. Institutional investors own 8.09% of the company’s stock.

About VolitionRX

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.